Longboard Pharmaceuticals Stock Forecast, Price & News

-1.13 (-8.70 %)
(As of 04/13/2021 12:00 AM ET)
Today's Range
Now: $11.86
50-Day Range N/A
52-Week Range
Now: $11.86
Volume26,450 shs
Average Volume54,798 shs
Market Capitalization$200.64 million
P/E RatioN/A
Dividend YieldN/A
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines for neurological diseases. Its products include LP352, a Phase I clinical trial product for the developmental and epileptic encephalopathies (DEEs) and refractory epilepsies; LP143, a product for amyotrophic lateral sclerosis and other neuroinflammatory disorders; and LP659, a product for multiple neuroinflammatory disorders. Longboard Pharmaceuticals, Inc. was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. The company was founded in 2020 and is based in San Diego, California.

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolNASDAQ:LBPH
Phone619 592 9775
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Market Cap$200.64 million
Next Earnings DateN/A
OptionableNot Optionable


Overall MarketRank

1.90 out of 5 stars

Medical Sector

92nd out of 2,019 stocks

Biotechnology Industry

8th out of 145 stocks

Analyst Opinion: 4.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
-1.13 (-8.70 %)
(As of 04/13/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LBPH News and Ratings via Email

Sign-up to receive the latest news and ratings for LBPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Longboard Pharmaceuticals (NASDAQ:LBPH) Frequently Asked Questions

Is Longboard Pharmaceuticals a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Longboard Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Longboard Pharmaceuticals stock.
View analyst ratings for Longboard Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Longboard Pharmaceuticals?

Wall Street analysts have given Longboard Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Longboard Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for LBPH?

5 brokers have issued 1-year price targets for Longboard Pharmaceuticals' shares. Their forecasts range from $27.00 to $37.00. On average, they anticipate Longboard Pharmaceuticals' stock price to reach $32.75 in the next year. This suggests a possible upside of 176.1% from the stock's current price.
View analysts' price targets for Longboard Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Longboard Pharmaceuticals' key executives?

Longboard Pharmaceuticals' management team includes the following people:
  • Mr. Kevin R. Lind, Pres, CEO & Director (Age 45)
  • Ms. Brandi L. Roberts, Chief Financial Officer (Age 47)
  • Mr. Chadwick J. Orevillo MPH, VP & Head of Operations
  • Megan E. Knight, Head of Investor Relations
  • Dr. Philip Perera, Chief Medical Officer (Age 68)

Who are some of Longboard Pharmaceuticals' key competitors?

When did Longboard Pharmaceuticals IPO?

(LBPH) raised $75 million in an initial public offering on Friday, March 12th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Evercore ISI, Guggenheim Securities and Cantor acted as the underwriters for the IPO.

What is Longboard Pharmaceuticals' stock symbol?

Longboard Pharmaceuticals trades on the NASDAQ under the ticker symbol "LBPH."

When does the company's quiet period expire?

Longboard Pharmaceuticals' quiet period expires on Wednesday, April 21st. Longboard Pharmaceuticals had issued 5,000,000 shares in its public offering on March 12th. The total size of the offering was $80,000,000 based on an initial share price of $16.00. During the company's quiet period, insiders and underwriters involved in the IPO are restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of Longboard Pharmaceuticals?

Shares of LBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Longboard Pharmaceuticals' stock price today?

One share of LBPH stock can currently be purchased for approximately $11.86.

How much money does Longboard Pharmaceuticals make?

Longboard Pharmaceuticals has a market capitalization of $200.64 million.

How many employees does Longboard Pharmaceuticals have?

Longboard Pharmaceuticals employs 6 workers across the globe.

What is Longboard Pharmaceuticals' official website?

The official website for Longboard Pharmaceuticals is

How can I contact Longboard Pharmaceuticals?

The company can be reached via phone at 619 592 9775.

This page was last updated on 4/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.